NCT06788626

Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment

• Status: Not Yet Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 390 (estimated)
• Sponsor: Wei Hu · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to learn if semaglutide works to treat acute ischemic stroke (AIS). It will also learn about the safety of semaglutide in AIS. The main question it aims to answer is: Does semaglutide improve the 90-days functional outcome in participants with acute large vessel occlusion who receive the endovascular treatment (EVT)? Researchers will compare semaglutide injection to non-injection to see if semaglutide works to improve the functional outcome in participants with EVT. Participants will: * Receive 0.5mg semaglutide injection before (Day 0) and 1 week (Day 7) after EVT , or EVT alone. * Have additional blood test before and after EVT. * Receive neurological assessment before EVT, Day 1, Day 3, Day 5-7 after EVT or on hospital discharge (whichever earlier), Day 90±14 after EVT. Audio or video of the assessment may be recorded if possible. * Receive brain CT + CT angiogram + CT perfusion and MRI after EVT, where the CT scan may be repetitive.

Conditions

• Acute Ischemic Stroke
• Large Vessel Occlusion
• Neuroprotective Drugs
• Endovascular Treatment

Interventions

Type	Name	Description
DRUG	Semaglutide 0.5 mg	0.5mg semaglutide injection before and 1 week after endovascular treatment.
OTHER	Standard medical treatment	Standard medical management

Timeline

• Start date: 2025-02-01
• Primary completion: 2028-02-01
• Completion: 2028-02-01
• First posted: 2025-01-23
• Last updated: 2025-01-23

Locations

1 site across 1 country: China